- TKMR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $101.0 million.
- TKMR is up 3.4% today from today's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in TKMR with the Ticky from Trade-Ideas. See the FREE profile for TKMR NOW at Trade-Ideas More details on TKMR: Tekmira Pharmaceuticals Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics; and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. Currently there are 6 analysts that rate Tekmira Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Tekmira Pharmaceuticals has been 2.5 million shares per day over the past 30 days. Tekmira has a market cap of $398.3 million and is part of the health care sector and drugs industry. Shares are up 140% year-to-date as of the close of trading on Tuesday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Tekmira Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income.